Overview
Services

FALCO HOLDINGS Co.,Ltd.

FALCO Holdings operates a diversified healthcare group comprising three core segments: clinical laboratory testing, dispensing pharmacy, and ICT services. Its primary subsidiary, Falco Biosystems, provides clinical specimen testing services to hospitals and clinics, and manufactures/sells in-vitro diagnostic pharmaceuticals and medical information systems. The group is complemented by pharmacy operations through Falco Pharmacies and Tulip Dispensing, and healthcare IT solutions (including electronic medical records) developed and sold by Medisage.

Market Cap
¥27.2B
US$173M
EV
¥16.0B
US$102M
Stock¥2,725▲+0.33%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
4.4
x
LTM EV/EBIT
6.2
x
LTM PER
13.1
x
LTM PBR
1.1
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-14.3%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
27.2BUS$173MMarket Cap1.26BUS$8.00M+ Debt8.68BUS$55.4M− Cash3.71BUS$23.7M− Inv. Sec.16.0BUS$102MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
50.0US$319M'22/346.9US$299M'23/343.0US$274M'24/343.3US$276M'25/343.6US$278M'26/3
EBITDA 5Y (¥B)
6.44US$41.1M'22/34.10US$26.1M'23/33.12US$19.9M'24/33.27US$20.9M'25/33.56US$22.7M'26/3
Net Income 5Y (¥B)
3.53US$22.5M'22/32.26US$14.4M'23/31.67US$10.6M'24/31.92US$12.2M'25/32.02US$12.9M'26/3
Capital Structure
95%
EquityD/E 0.05xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
14.4US$92.1M4.07US$25.9M'22/315.2US$97.1M2.80US$17.9M'23/313.7US$87.3M0.82US$5.21M'24/313.1US$83.5M1.44US$9.16M'25/313.1US$83.7M1.26US$8.00M'26/3
Shareholders
Top 10 hold 40.3%
1
BML,INC.
9.84%
2
The Master Trust Bank of Japan, Ltd. (Trust Account)
9.01%
3
FALCO HOLDINGS Co.,Ltd. Employee Stock Ownership Association
4.34%
4
Hikari Tsushin KK Investment Business Limited Liability Partnership (General Partner: Hikari Tsushin, Inc.)
3.96%
5
MATSUMOTO YUSHI-SEIYAKU CO.,LTD.
3.01%
6
Nomura Trust and Banking Co., Ltd. (Trust Account for FALCO HOLDINGS Co.,Ltd. Employee Stock Ownership Association)
2.89%
7
Custody Bank of Japan, Ltd. (Trust Account)
2.19%
8
Osaka Small and Medium Business Investment & Consultation Co., Ltd.
2.02%
9
Kanji AKAZAWA
1.63%
10
Kajita Kōmuten Co., Ltd.
1.36%
Management
8 officers
Tadashi YASUDA
Representative Director, President and Executive Officer
Feb 1995 Joined Falco Biosystems Co., Ltd. (now the Company) Dec 1998 General Manager, Corporate Planning Department, the Company Jul 2000 General Manager, Accounting Department, the Company Apr 2003 General Manager, Accounting Department and General Manager, Corporate Planning Office, the Company Dec 2003 Director, General Manager, Accounting Department and General Manager, Corporate Planning Office, the Company Oct 2005 Director, General Manager, Corporate Planning Office, the Company Dec 2005 Managing Director, General Manager, Corporate Planning Division and General Manager, Business Development Division, the Company Sep 2006 Managing Director, General Manager, Corporate Planning Division and General Manager, Bio Business Division, the Company Sep 2007 Managing Director, General Manager, Planning and Administration Division, the Company Jan 2008 Senior Managing Director, General Manager, Planning and Administration Division, the Company Mar 2010 Senior Managing Director, General Manager, Strategy Office and General Manager, Pharma Business Office, the Company Aug 2010 Representative Director, President, Falco Business Support Co., Ltd. Jun 2013 Director, General Manager, Strategy Office, the Company Jun 2015 Representative Director, Falco Biosystems Co., Ltd. Jun 2015 Representative Director, Falco Pharmacies Co., Ltd. Jun 2015 Director and Vice President, General Manager, Strategy Office, the Company Jun 2017 Representative Director, President, General Manager, Strategy Office, the Company Jul 2017 Representative Director, President, General Manager, Administration Office, the Company Jun 2018 Representative Director, Chairman, Falco Biosystems Co., Ltd. Jun 2018 Representative Director, Chairman, Falco Business Support Co., Ltd. Jun 2018 Representative Director, President, the Company Apr 2019 Representative Director, President (concurrently General Manager, Corporate Planning Office), the Company Jun 2021 Representative Director, President, the Company; Representative Director, Chairman, Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) (current) Jun 2023 Representative Director, President and Executive Officer, the Company Jun 2024 Representative Director, President and Executive Officer, the Company (current)
1958-08-09
Takashi FUKUI
Director, Executive Vice President and Executive Officer, General Manager, Clinical Business Office, General Manager, Genome Business Office
Nov 2002 Joined Falco Biosystems Co., Ltd. (now the Company) Apr 2019 Group Leader, Testing Group (Deputy General Manager), Biomedical Department, Falco Biosystems Co., Ltd. Jun 2019 Acting Deputy General Manager, Biomedical Business Division, Falco Biosystems Co., Ltd. Apr 2020 General Manager, Biomedical Business Division, Falco Biosystems Co., Ltd. Jun 2021 Director, Deputy General Manager, Clinical Business Office, the Company; Director, General Manager, Biomedical Business Division, Falco Biosystems Co., Ltd. Jun 2022 Director, General Manager, Genome Business Office, the Company; Managing Director, General Manager, Biomedical Business Division, Falco Biosystems Co., Ltd. Jun 2023 Director, Managing Executive Officer, General Manager, Genome Business Office, the Company; Senior Managing Director, General Manager, Biomedical Business Division, Falco Biosystems Co., Ltd. Jun 2024 Director, Senior Managing Executive Officer, General Manager, Genome Business Office, the Company; Representative Director, Chairman, Falco Biosystems Co., Ltd. (concurrently General Manager, Biomedical Business Division); Director, Chairman, Falco Pharmacies Co., Ltd.; Chairman, Tulip Chōzai Co., Ltd.; Representative Director, Medisage Co., Ltd. Jun 2025 Director, Executive Vice President and Executive Officer, General Manager, Genome Business Office, the Company; Representative Director, President, Medisage Co., Ltd. (current) Jun 2026 (scheduled) Director, Executive Vice President and Executive Officer (concurrently General Manager, Clinical Business Office and General Manager, Genome Business Office), the Company Jun 2026 Representative Director, President, Falco Biosystems Co., Ltd. (current); Director, Falco Pharmacies Co., Ltd. (current); Director, Medisage Co., Ltd. (current)
1965-10-12
Hisayuki OMA
Director, Executive Officer, General Manager, Pharma Business Office
Sep 2007 Joined Falco Biosystems Co., Ltd. (now the Company) Jul 2015 Executive Officer, General Manager, Accounting Department, Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) Jun 2016 Director, Tulip Chōzai Co., Ltd.; Managing Executive Officer, Falco Pharmacies Co., Ltd. Jul 2016 Managing Executive Officer, Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) Jun 2017 Director, Falco Pharmacies Co., Ltd. Jan 2019 Managing Executive Officer, General Manager, Accounting Department, Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) Jun 2019 Director, General Manager, Planning Office, General Manager, Legal Office, General Manager, General Affairs Department and General Manager, Accounting Department, Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) Jul 2019 Executive Officer, Deputy General Manager, Administration Office, the Company Jun 2022 Managing Director, General Manager, Planning Office and General Manager, Accounting Department, Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) Jul 2022 Executive Officer, General Manager, Administration Office, the Company; Managing Director, General Manager, Administration Division, Medisage Co., Ltd. Jun 2024 Executive Officer, Deputy General Manager, Pharma Business Office, the Company; Director, Falco Pharmacies Co., Ltd.; Representative Director, President, Tulip Chōzai Co., Ltd. (current) Jun 2025 Director, Executive Officer, General Manager, Pharma Business Office, the Company (current); Representative Director, Falco Pharmacies Co., Ltd. Jun 2026 Representative Director, President, Falco Pharmacies Co., Ltd. (current)
1969-11-05
Shuhei KURODA
Director, Executive Officer, General Manager, Administration Office, Deputy Head, ICT Business Office
Mar 2012 Joined Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) Apr 2017 General Manager, Accounting Department, Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) Jun 2019 Director, Falco Pharmacies Co., Ltd.; Director, Tulip Chōzai Co., Ltd. Jun 2021 Director, Falco Business Support Co., Ltd. (now Medisage Co., Ltd.) Jun 2022 Executive Officer, Deputy General Manager, Clinical Business Office (concurrently Deputy General Manager, Genome Business Office), the Company; Director, Falco Biosystems Co., Ltd. Jul 2022 Director, Medisage Co., Ltd.; Assistant to General Manager, ICT Business Division (Deputy General Manager) Oct 2022 Executive Officer, Deputy General Manager, Restructuring Promotion Office (concurrently Deputy General Manager, Clinical Business Office and Deputy General Manager, Genome Business Office), the Company Jun 2023 Executive Officer, General Manager, Corporate Planning Office (concurrently Deputy Head, ICT Business Office and Deputy General Manager, Genome Business Office), the Company Jun 2024 Executive Officer, General Manager, Administration Office (concurrently Deputy Head, ICT Business Office and Deputy General Manager, Genome Business Office), the Company; Managing Director, General Manager, Administration Division and Assistant to General Manager, ICT Business Division (Deputy General Manager), Medisage Co., Ltd. Jun 2025 Director, Executive Officer, General Manager, Administration Office (concurrently Deputy Head, ICT Business Office), the Company; Senior Managing Director, General Manager, Administration Division, Medisage Co., Ltd. Aug 2025 Director, Executive Officer, General Manager, Administration Office, General Manager, IR Office (concurrently Deputy Head, ICT Business Office), the Company (current) Jun 2026 Director, Executive Officer, General Manager, Corporate Planning Office, General Manager, Administration Office (concurrently Deputy Head, ICT Business Office), the Company (scheduled) Jun 2026 Representative Director, Executive Vice President, Medisage Co., Ltd. (concurrently Assistant to Head, ICT Business Division, Deputy Head) (current)
1973-05-22
Kei SHIMADA
Director, Executive Officer, General Manager, ICT Business Office, Deputy General Manager, Genome Business Office
Mar 2005 Joined Falco Biosystems Co., Ltd. (now the Company) Jul 2022 Deputy General Manager, Sales Unit, ICT Business Division, Medisage Co., Ltd. Jun 2024 General Manager, Sales Unit, ICT Business Division, Medisage Co., Ltd. Jun 2024 Deputy General Manager, ICT Business Office, the Company; Director, Deputy Head, ICT Business Division, Medisage Co., Ltd. Jun 2025 Director, Executive Officer, General Manager, ICT Business Office (concurrently Deputy General Manager, Genome Business Office), the Company (current); Senior Managing Director, Head, ICT Business Division, Medisage Co., Ltd. Jun 2026 Representative Director, President, Medisage Co., Ltd. (concurrently Head, ICT Business Division) (current)
1973-07-16
Shoji TAKAI
Director, Audit and Supervisory Committee Member
Oct 1993 Joined Chuo Audit Corporation (later Misuzu Audit Corporation), Kyoto Office Apr 1997 Registered as Certified Public Accountant Jul 2004 Partner, Chuo Aoyama Audit Corporation (later Misuzu Audit Corporation) Mar 2007 Partner, Kyoto Audit Corporation (now PwC Japan LLC) Jul 2019 Vice President, Japanese Institute of Certified Public Accountants, Kyoto-Shiga Chapter Jul 2023 Established Shoji Takai CPA Office; Representative (current) Jun 2024 Director, the Company Feb 2025 Member, Management Oversight Committee, Hikari Audit Corporation (current) Jun 2025 Director, Audit and Supervisory Committee Member, the Company (current)
1965-05-01
Mitsuo ISODA
Director, Audit and Supervisory Committee Member
Apr 1995 Registered as attorney (Osaka Bar Association) Apr 1995 Joined Miyake & Partners (now Miyake Law Office LPC) Jun 2001 Completed LL.M. program, Harvard Law School Aug 2001 Trainee, New York Office, Pillsbury Winthrop Feb 2002 Registered as attorney in New York State (at that time) Jul 2002 Partner, Miyake Law Office LPC Jun 2014 Outside Audit & Supervisory Board Member, Haseko Corporation (current) Jun 2016 Outside Director, Morita Holdings Corporation (current) Apr 2018 Civil Mediation Commissioner, Osaka Summary Court (current) May 2019 Representative Member, Miyake Law Office LPC (current) Jun 2025 Director, Audit and Supervisory Committee Member, the Company (current)
1970-01-07
Kaiko KOSAKA
Director, Audit and Supervisory Committee Member
Oct 2002 Registered as attorney; joined Iro Law Office Jan 2009 Staff Attorney, Iro Law Office (current) Apr 2012 Part-time Lecturer, Doshisha Law School Jun 2016 Outside Audit & Supervisory Board Member, Nihon Yamamura Glass Co., Ltd. Jun 2017 Outside Director, Audit and Supervisory Committee Member, Nihon Yamamura Glass Co., Ltd. (current) Jun 2017 Outside Audit & Supervisory Board Member, Asia Pacific Trade Center Co., Ltd. (current) Mar 2018 Outside Audit & Supervisory Board Member, Toyo Tanso Co., Ltd. Jun 2018 Audit & Supervisory Board Member, the Company Jun 2021 Director, Audit and Supervisory Committee Member, the Company (current) Mar 2022 Outside Director, Toyo Tanso Co., Ltd. (current)
1976-09-20
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-05
Q1 Earnings Flash
FY ending Mar 2027
EDINETAmended
2026-07-24
Amended Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-06-24
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-02-10
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-11
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2025-08-08
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-23
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-12
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-12
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-09
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-21
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-13
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-14
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-23
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-03-10
Securities Registration Statement
EDINET
2023-02-10
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-10
Quarterly Securities Report
EDINET
2022-06-22
Annual Securities Report
EDINET
2022-02-10
Quarterly Securities Report
EDINET
2021-11-11
Quarterly Securities Report
EDINET
2021-08-10
Quarterly Securities Report
EDINET
2021-06-22
Annual Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →